Robert Flynn, MD
Gastroenterology · North Chesterfield, VANPI 1982812681
Payments from drug & device makers
Across 472 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$863
- Sanofi$509
- Johnson & Johnson$462
- QOL Medical, LLC$230
- plus $2K from 22 others
What the payments were for
- Food & beverage$8,508100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 191 | $3,600 |
| Takeda Pharmaceuticals U.S.A., Inc. | 83 | $1,015 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $863 |
| Sanofi | 19 | $509 |
| Johnson & Johnson | 26 | $462 |
| QOL Medical, LLC | 10 | $230 |
| Pfizer | 12 | $221 |
| Ardelyx, Inc. | 7 | $207 |
| Gilead | 8 | $167 |
| Medtronic | 2 | $130 |
| Merck | 7 | $119 |
| Bristol Myers Squibb | 8 | $117 |
| Braintree Laboratories, Inc. | 5 | $98 |
| Lilly USA, LLC | 4 | $89 |
| Ironwood Pharmaceuticals, Inc | 5 | $85 |
| Ferring Pharmaceuticals Inc. | 4 | $74 |
| Celltrion USA Inc. | 3 | $74 |
| Phathom Pharmaceuticals, Inc. | 4 | $63 |
| Sandoz | 3 | $62 |
| Organon | 3 | $61 |
| Madrigal Pharmaceuticals | 3 | $58 |
| Pharmacosmos Therapeutics Inc. | 3 | $49 |
| UCB, Inc. | 2 | $47 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,528 in reported general payments places this provider in the 65th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 23 | $578,146 |
| CreonLipase/Protease/Amylase | 76 | $130,926 |
| LinzessLinaclotide | 96 | $70,335 |
| XifaxanRifaximin | 17 | $53,958 |
| Mesalamine | 48 | $39,670 |
| Dexlansoprazole DrDexlansoprazole | 83 | $27,094 |
| IbsrelaTenapanor Hcl | 11 | $19,330 |
| AprisoMesalamine | 12 | $18,373 |
| VemlidyTenofovir Alafenamide | 13 | $17,299 |
| Mesalamine ErMesalamine | 56 | $11,023 |
| Pantoprazole Sodium | 451 | $10,028 |
| MotegrityPrucalopride Succinate | 13 | $9,765 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 41 | $6,907 |
| Esomeprazole Magnesium | 147 | $6,478 |
| CholestyramineCholestyramine (With Sugar) | 78 | $4,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $462 | $578,14623 claims |
| AbbVieCreon, Linzess | $3,600 | $201,261172 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Apriso | $863 | $72,33029 claims |
| Ardelyx, Inc.Ibsrela | $207 | $19,33011 claims |
| GileadVemlidy | $167 | $17,29913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,015 | $9,76513 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $74 | $6,90741 claims |
| SandozLansoprazole | $62 | $2,89919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in North Chesterfield
- Omer KhalidNorth Chesterfield$1.2M
- Larry ClarkLynchburg$8.5M
- Arun SanyalRichmond$5.5M
- Mitchell ShiffmanNewport News$4.7M
- Jasmohan BajajRichmond$4.4M
- Michael FuchsRichmond$1.9M
- Stephen CaldwellCharlottesville$1.8M
- Nirish ShahRoanoke$1.7M
- Michael RyanNorfolk$1.5M
- Binu JohnRichmond$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.